US · VCEL
Vericel Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02139
- Website
- vcel.com
Price · as of 2025-12-31
$35.57
Market cap 1.8B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $47.91 | +34.69% |
| Intrinsic Value(DCF) | $21.78 | -38.77% |
| Graham-Dodd Method(GD) | $8.64 | -75.7% |
| Graham Formula(GF) | $7.78 | -78.14% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $44.00 | $43.39 | $0.00 | $0.00 | $694.64 |
| 2012 | $25.00 | $10.00 | $0.00 | $0.00 | $0.00 |
| 2013 | $3.36 | $112.49 | $0.00 | $0.00 | $5.45 |
| 2014 | $3.69 | $23,197.63 | $43,688.41 | $0.00 | $0.00 |
| 2015 | $4.33 | $41.30 | $307,663.37 | $0.00 | $0.00 |
| 2016 | $2.85 | $20.74 | $175,941.78 | $0.00 | $0.00 |
| 2017 | $11.55 | $33.50 | $9,337.60 | $0.00 | $0.00 |
| 2018 | $20.29 | $52.71 | $294.27 | $1.53 | $0.00 |
| 2019 | $14.02 | $81.15 | $150.33 | $1.42 | $0.00 |
| 2020 | $46.68 | $145.86 | $24.35 | $3.29 | $0.84 |
| 2021 | $33.99 | $43.54 | $2.82 | $2.86 | $0.00 |
| 2022 | $29.40 | $39.60 | $0.00 | $2.31 | $0.00 |
| 2023 | $45.20 | $42.88 | $0.00 | $4.41 | $0.00 |
| 2024 | $49.56 | $69.16 | $0.00 | $7.04 | $5.82 |
| 2025 | $35.36 | $47.91 | $0.27 | $8.64 | $7.78 |
AI valuation
Our deep-learning model estimates Vericel Corporation's (VCEL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $47.91
- Current price
- $35.57
- AI upside
- +34.69%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$21.78
-38.77% upside
Graham-Dodd
$8.64
-75.7% upside
Graham Formula
$7.78
-78.14% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VCEL | Vericel Corporation | $35.57 | 1.8B | +35% | -39% | -76% | -78% | 108.30 | 5.04 | 6.48 | 57.69 | 180.50 | 5.13 | 74.42% | 4.00% | 5.98% | 5.11% | 3.57% | 3.59% | 0.27 | 7.10 | 5.03 | 4.52 | -0.13 | 6000.00% | 1645.00% | -52588.00% | 1.38% | 1.06 | 8.42% | 0.00% | 0.00% | 1.57% | 158.24 | 70.62 | 6.33 | 8.10 |
| AUPH | Aurinia Pharmaceuticals I… | $14.17 | 1.87B | +206% | +451% | +6% | +317% | 6.65 | 3.28 | 6.75 | 12.42 | 0.13 | 3.31 | 88.46% | 37.06% | 101.47% | 59.91% | 58.85% | 44.11% | 0.13 | 24.23 | 5.25 | 4.69 | -0.04 | 516718.00% | 2038.00% | 20699.00% | 7.09% | 1.45 | 75.96% | 0.00% | 0.00% | 5.21% | 15.12 | 11.71 | 5.60 | 6.99 |
| EWTX | Edgewise Therapeutics, In… | $30.44 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| GPCR | Structure Therapeutics In… | $62.98 | 3.63B | — | — | — | — | -26.37 | 2.46 | — | -16.39 | -1028.46 | 2.46 | 0.00% | — | — | -11.86% | -570.89% | -11.35% | 0.00 | — | 24.81 | 22.85 | 5.69 | 256.00% | — | 9149.00% | -6.06% | -3.51 | -730.15% | 0.00% | 0.00% | 16.85% | -12.94 | -10.11 | — | 33.44 |
| HRMY | Harmony Biosciences Holdi… | $28.54 | 1.64B | +155% | +609% | +1% | +178% | — | 1.91 | 1.91 | 4.41 | — | 2.13 | 77.16% | 24.00% | 18.27% | 0.00% | 43.46% | 0.00% | 0.28 | 14.23 | 3.60 | 3.46 | -2.01 | 797.00% | 2151.00% | 5909.00% | 20.94% | 1.38 | 98.30% | 0.00% | — | 14.52% | 5.40 | 3.24 | 1.30 | 4.50 |
| MESO | Mesoblast Limited | $15.85 | 2.04B | +203% | -57% | — | — | -17.02 | 2.91 | 101.06 | -23.15 | — | 67.85 | 70.17% | -363.08% | -593.92% | -18.95% | -11.34% | -14.05% | 0.21 | -2.72 | 1.99 | 1.72 | 0.45 | -562.00% | 19139.00% | 388.00% | -2.92% | -0.49 | -9.21% | 0.00% | 0.00% | 5.14% | -27.31 | -33.64 | 99.14 | 3.68 |
| MNKD | MannKind Corporation | $3.28 | 1.01B | +882% | +28% | — | -83% | 158.21 | -18.18 | 2.66 | 29.19 | — | -7.50 | 82.47% | 11.12% | 1.68% | -9.03% | -19.22% | 0.99% | -0.92 | 2.81 | 1.70 | 1.23 | -1.01 | -7942.00% | 2223.00% | -5829.00% | 1.48% | 0.11 | -6.78% | 0.00% | 0.00% | 3.16% | 20.70 | 58.68 | 2.30 | -4.20 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| OCUL | Ocular Therapeutix, Inc. | $8.94 | 1.95B | +214% | -39% | — | +53% | -7.73 | 3.14 | 39.67 | -5.60 | -47.16 | 3.14 | 87.31% | -521.04% | -513.17% | -54.85% | 13699.49% | -42.01% | 0.12 | -22.82 | 15.39 | 15.11 | 2.63 | 1639.00% | -1867.00% | 5952.00% | -10.55% | -4.03 | 11004.21% | 0.00% | 0.00% | 16.58% | -5.18 | -6.45 | 26.99 | 6.07 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
- CEO
- Dominick C. Colangelo
- Employees
- 357
- Beta
- 1.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($21.78 ÷ $35.57) − 1 = -38.77% (DCF, example).